Analyst Ratings For Cipher Pharmaceuticals (TSE:CPH)
Today, Cipher Pharmaceuticals (TSE:CPH) stock received an upgrade by Bloom Burton from Hold to Buy.
There are 2 hold ratings, 1 buy rating on the stock.
The current consensus rating on Cipher Pharmaceuticals (TSE:CPH) is Hold (Score: 2.33) with a consensus target price of C$6.38 per share, a potential .
Some recent analyst ratings include
- 5/12/2017-Bloom Burton Upgrade from a “Hold ” rating to a ” Buy” rating.
- 5/2/2017-TD Securities Reiterated Rating of Hold.
- 8/11/2016-GMP Securities was Downgraded by analysts at GMP Securities from a “Buy ” rating to a ” Hold” rating.
About Cipher Pharmaceuticals (TSE:CPH)
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Recent Trading Activity for Cipher Pharmaceuticals (TSE:CPH)
Shares of Cipher Pharmaceuticals closed the previous trading session at 5.06 up +0.06 1.20% with 32,258 shares trading hands.
